文献速递急性肾损伤水电解质与酸碱

癌症患者中唑来膦酸相关范可尼综合征

Zoledronic Acid-Associated Fanconi Syndrome in Patients With Cancer.
PubMed 文献 · Am J Kidney Dis · 2022-02-24

本文报告4例接受唑来膦酸治疗的恶性肿瘤患者,在输注后约1周出现范可尼综合征,表现为急性肾损伤、低碳酸氢盐血症、尿酸化异常、低磷血症、低钾血症及尿氨基酸排泄增加或肾性糖尿。作者认为时间关联高度提示唑来膦酸相关范可尼综合征,均需停用唑来膦酸并持续补充电解质,提醒肾内科与肿瘤科医生认识该并发症。

要点

  • 4例恶性肿瘤患者接受唑来膦酸后约1周出现范可尼综合征。
  • 均表现为急性肾损伤、低碳酸氢盐血症、尿酸化异常、低磷血症、低钾血症。
  • 所有患者需停用唑来膦酸并持续补充电解质。

核心结论

  • 基于唑来膦酸输注与电解质异常的时间关联,每例均高度提示唑来膦酸相关范可尼综合征。
  • 肾内科与肿瘤科医生应认识该并发症,并考虑唑来膦酸为新发范可尼综合征的可能诱因。

研究设计与样本

  • 本文为4例接受唑来膦酸治疗的恶性肿瘤患者的病例报告。

主要发现

  • 4例患者在唑来膦酸治疗后约1周出现广泛近端小管功能障碍(范可尼综合征)证据。
  • 就诊时所有患者均有急性肾损伤、低碳酸氢盐血症、尿酸化异常、低磷血症、低钾血症及尿氨基酸排泄增加或肾性糖尿。
  • 因表现严重,所有患者均需停用唑来膦酸并持续补充电解质。

关键数值与推荐

  • 唑来膦酸几乎完全经肾脏排泄,肾清除率下降可致药物蓄积和潜在肾毒性。
  • 静脉双膦酸盐相关急性肾损伤虽不常见,但已有描述,包括肾小管间质性肾炎、急性肾小管坏死及局灶节段性肾小球硬化等不同模式。

临床怎么用

  • 作者提醒肾内科与肿瘤科医生应认识唑来膦酸相关范可尼综合征,并考虑唑来膦酸为新发范可尼综合征的可能诱因。
  • 所有患者在出现严重表现后均需停用唑来膦酸并持续补充电解质。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Zoledronic acid (ZA) is an antiresorptive agent typically used for fracture prevention in postmenopausal osteoporosis, malignancy-associated metastatic bone lesions, and as a treatment for hypercalcemia. ZA is excreted almost entirely by the kidney; as a result, a reduction in renal clearance can lead to its accumulation and potential renal toxicity. Although uncommon, acute kidney injury (AKI) from intravenous bisphosphonates has been described, with different patterns including tubulointerstitial nephritis, acute tubular necrosis, as well as focal segmental glomerulosclerosis. Here we present 4 patients with an underlying malignancy who each developed evidence of generalized proximal tubular dysfunction, also known as Fanconi syndrome, approximately 1 week after receiving treatment with ZA. On presentation, all patients had AKI, low serum bicarbonate levels, abnormal urinary acidification, hypophosphatemia, hypokalemia, and increased urine amino acid excretion or renal glycosuria. Based on the temporal association between ZA infusion and the development of these electrolyte abnormalities, each case is highly suggestive of ZA-associated Fanconi syndrome. Due to the severity of presentation, all required discontinuation of ZA and ongoing electrolyte repletion. Nephrologists and oncologists should be aware of this complication and consider ZA as a possible trigger of new-onset Fanconi syndrome.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Portales-Castillo I, Mount DB, Nigwekar SU, et al. Zoledronic Acid-Associated Fanconi Syndrome in Patients With Cancer. Am J Kidney Dis. 2022. PMID: 35219759. doi:10.1053/j.ajkd.2021.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。